Human and murine osteocalcin genes demonstrate similar cell-specific expression patterns despite significant differences in gene locus organization and sequence variations in cis-acting regulatory elements. To investigate whether differences in these regulatory regions result in an al- 
INTRODUCTION
Osteocalcin is the most abundant noncollagenous protein expressed in bone (1, 2) , with its expression limited specifically to cells of the osteoblast lineage, including mature osteoblasts, osteocytes, and hypertrophic chondrocytes (3) (4) (5) (6) . There is also some evidence for low levels of osteocalcin expression in megakaryocytes, platelets (7) , and brain (8) . Despite its well characterized specificity of expression, the precise function of osteocalcin in bone remodeling is not clear. The location of osteocalcin at bone-forming surfaces (9, 10) and the increased bone mineralization observed in osteocalcin gene knockout mice (11) and warfarin-treated rats (12, 13) supports a role for osteocalcin in suppression of bone mineralization. Alternatively, osteocalcin has been suggested to increase bone resorption through osteoclast recruitment (10, 14) .
Serum levels of osteocalcin increase in humans (15) and rats (16) after injection with 1,25-dihydroxyvitamin D 3 [1, 2 D 3 ] , and increased osteocalcin mRNA expression occurs in rat femurs 6 h after 1,25-(OH) 2 D 3 treatment in vivo (17) . Expression of osteocalcin mRNA and protein is stimulated by 1,25-(OH) 2 D 3 in rat osteoblastic cell lines (18) (19) (20) (21) (22) and in human cultured primary osteoblasts (23, 24) , as well as in transfection studies of the human (25, 26) and rat (27) (28) (29) osteocalcin genes.
Stimulation of gene transcription by 1,25-(OH) 2 D 3 depends on binding of vitamin D receptor/retinoid X receptor (VDR/RXR) heterodimers or VDR homodimers to specific vitamin D-responsive elements (VDREs) within the human and rat osteocalcin gene promoters (30) (31) (32) . The organizations of the human, rat, and mouse osteocalcin genes differ, however, with some rat and all mouse strains studied, having a cluster of osteocalcin-related genes rather than a singlecopy gene as described in the human (18, (33) (34) (35) . Despite these differences, the same pattern of tissuespecific expression is shared by the three species, and the promoters of the two mouse osteocalcin genes exhibit the same modular organization described in the rat and human genes, including a VDRE consensus sequence at a similar distance upstream of the transcription start site (33) . Cis-acting elements thought to direct tissue-specific and hormone-responsive osteocalcin gene transcription differ, however, between species (33, 34) , and trans-acting factors that bind to these regions are also likely to vary (34, 36, 37) , leading to potential variation in transcriptional control mechanisms. Supporting this concept, recent studies have verified such a species-related difference, showing the mouse osteocalcin gene to be down-regulated rather than induced by 1,25-(OH) 2 D 3 in vivo and in vitro (38, 39) . In each of these studies, the inhibitory effect was demonstrated on the endogenous mouse osteocalcin gene, and direct comparisons of rat and mouse osteocalcin-regulatory activities were made in transfected rat and mouse cell lines. In the present study, basal tissue-specific and 1,25-(OH) 2 D 3 -responsive regulation by the mouse and human osteocalcin promoters were directly compared in transgenic mice carrying a reporter transgene in an osteoblast-targeting vector based on 5Ј-and 3Ј-sequences from the human osteocalcin gene locus.
The human regulatory sequences conferred a spatially restricted transgene expression pattern virtually identical to that of the endogenous osteocalcin gene, confirming that the cis-and trans-acting mechanisms directing the restricted pattern of osteocalcin gene expression are conserved across species. However, although the human osteocalcin-directed transgene was up-regulated by 1,25-(OH) 2 D 3 treatment, endogenous mouse osteocalcin gene expression was not induced by 1,25-(OH) 2 D 3 treatment in transgenic or nontransgenic mice, a confirmation of previous reports (38, 39) . Clearly, the vitamin D responsiveness of the osteocalcin gene does differ between species, and this variation is not due simply to differences in the cellular milieu in human and murine bone.
RESULTS

Transgene Expression Analyses
In the two sublines of OSCAT8 transgenic mice, transgene expression was detectable only in RNA preparations from bone tissues (Fig. 1A) , with no detectable expression in any other tissue, including brain or kidney, in either subline and no expression detectable in any nontransgenic tissues. Quantification of transgene expression normalized to the 18S RNA signal indicated that transgene expression in bones from the high copy number animals (OST2) was 8-fold higher than in low copy number (OST1) animals. As the OST2 line carries approximately 60 transgene copies compared with the two copies in OST1 mice, the OSCAT8 construct therefore does not confer copy numberindependent transgene expression.
Measurement of chloramphenicol acetyl transferase (CAT) enzyme activity in protein extracts from transgenic tissues was consistent with the Northern blot results. In both OST1 and OST2 animals, substantial transgene activity was detected in calvarial and femoral extracts but not in extracts from other tissues, with greater activity in calvarial preparations (Fig. 1B) . CAT activity levels in nonosseous tissues were negligible and did not differ between OST and wild type mice. As in the RNA analysis, greater transgene activity was seen in mice with higher transgene copy number; activities in calvarial and femoral extracts were 8-and 2-fold higher, respectively, in OST2 than in OST1 mice.
In femoral, tibial, calvarial, and vertebral sections from 8-week-old OST2 mice, CAT protein was immunohistochemically detected in cuboidal and flattened osteoblasts, osteocytes, and hypertrophic chondrocytes (femurs shown in Fig. 2, A-D) . Positively stained osteocytes were located close to bone-forming surfaces. Osteoblastic transgene expression was detected on trabecular bone surfaces and along endosteal and periosteal surfaces of cortical bone. Trabecular CAT protein stained surface in the femoral metaphysis was 27% of the trabecular bone surface. CAT protein was not detectable by immunohistochemistry in OST1 mice or in bones from nontransgenic mice (Fig. 2E) .
The pattern of transgene expression detected by in situ hybridization reflected that observed by immunohistochemistry (Fig. 3, A and B) , with CAT mRNA detected in flattened and cuboidal osteoblasts on both trabecular and cortical surfaces, in osteocytes and in hypertrophic chondrocytes. Few positively stained osteocytes, all of them immediately adjacent to positively stained osteoblastic surfaces, were detected by in situ hybridization. No specific transgene signal was detected by immunohistochemistry or in situ hybridization in bones from nontransgenic animals (Fig. 3 , E and F). Sections hybridized to sense strand probes or to antisense probes, but without anti-digoxigenin antibody, were similarly devoid of positive signal (Fig. 3 , C and D). Transgene expression followed osteocalcin expression at the single-cell level, shown by in situ hybridization on serial sections (Fig. 3, G and H) . In no area did CAT expression overlap regions of acid phosphatase activity in the same or adjacent sections (Fig.  3I) . Osteocalcin mRNA was detectable in megakaryocytes of both transgenic and nontransgenic mice by in situ hybridization in some sections only, but transgene mRNA expression was not detected in megakaryocytes by this technique, even after 1,25-(OH) 2 D 3 treatment.
1,25(OH) 2 D 3 Response
Osteoblastic cultures from OST2 transgenic calvariae responded to 1,25-(OH) 2 D 3 treatment with a significant increase in transgene activity (P ϭ 0.003 compared with vehicle-treated OST2 cultures). In contrast to this elevation of transgene expression by 1,25-(OH) 2 D 3 , there was a slight but nonsignificant decrease in endogenous osteocalcin released into cell culture supernatants in both OST2 (P ϭ 0.08) and FVB/N (P ϭ 0.13) cultures (Fig. 4) .
Consistent with calvarial culture results, a significant increase in transgene mRNA levels after 1,25-(OH) 2 D 3 treatment of OST1 and OST2 mice fed the high calcium (HighCa) diet was detected by Northern blot. Transgene mRNA levels in bones reached maximal A, Northern blot analysis of transgene expression in transgenic (OST1, OST2) and nontransgenic (FVB/N) mice. Bone (femur and calvaria), brain, liver, kidney, muscle, heart, and lung were collected from sublines carrying low (OST1) and high (OST2) numbers of copies of the OSCAT transgene and from FVB/N mice. Total RNA was analyzed by Northern blots probed for CAT (upper panel) and 18S RNAs (lower panel). The doublet of CAT expression in the OST2 bone may be due to alternative mRNA processing in the SV40 sequence included in the OSCAT8 construct (70) or may result from retardation of the mRNA by the 18S ribosomal RNA. B, CAT enzyme activity in tissues from transgenic and nontransgenic mice. Black bars represent activity from OST2; white bars indicate activity from OST1; and stippled bars depict activity from FVB/N tissues. Each assay was performed in triplicate, and the results are the mean Ϯ SEM of two to six experiments.
increases of similar magnitude in both low (20.5 Ϯ 9.7) and high (17.0 Ϯ 2.5) copy number mice at 6 h after 1,25-(OH) 2 D 3 treatment. In contrast, the endogenous osteocalcin mRNA level was not significantly changed by 1,25-(OH) 2 D 3 treatment in either transgenic line or in nontransgenic FVB/N mice (Fig. 5, A and B) . Baseline osteocalcin mRNA levels were lower in uninjected OST1 and OST2 mice than in FVB/N mice, with the following OC/18S mRNA ratios: FVB/N, 1.7Ϯ 0.3; OST1, 0.3 Ϯ 0.2; OST2, 0.5 Ϯ 0.3, P ϭ 0.045.
The SrCl 2 diet significantly reduced serum osteocalcin levels in both transgenic and nontransgenic mice (P ϭ 0.004). Levels in untreated FVB/N mice fed the SrCl 2 diet were 93.5 Ϯ 11.7 compared with 125.7 Ϯ 8.6 in low calcium-fed (LowCa) mice. In OST2 mice, levels were 78.6 Ϯ 7.8 on SrCl 2 and 103.8 Ϯ 11.2 on LowCa. The lower level of serum osteocalcin in OST2 mice compared with FVB/N was also statistically significant (P ϭ 0.048). This reduction in serum osteocalcin in OST2 mice and the reduction in osteocalcin In femurs of 8-week-old transgenic mice, CAT was detected: A, in both cuboidal and flattened osteoblasts and osteocytes in trabeculae; B, in cuboidal osteoblasts and osteocytes on endosteal surfaces, but not in the marrow; C, in osteoblasts on the periosteal surface; and D, in hypertrophic chondrocytes at the base of active chondrocyte stacks in the growth plate. E, No CAT-specific staining was detected in nontransgenic FVB/N bones by immunohistochemistry. Magnification: 400ϫ. b, Bone; c, chondrocyte; m, marrow; ob, osteoblast; oy, osteocyte; hc, hypertrophic chondrocyte. mRNA levels in OST1 and OST2 mice described above may reflect competition for transcriptional regulatory factors by the large number (40) of integrated OSCAT8 transgene copies. Treatment of the mice with 1,25-(OH) 2 D 3 did not significantly alter serum osteocalcin levels at any time after hormone injection, regardless of dietary manipulations or transgene status.
Similar CAT responses to 1,25-(OH) 2 D 3 treatment were seen in mice fed SrCl 2 and LowCa diets. Transgene mRNA levels were maximally increased 6 h after 1,25-(OH) 2 D 3 treatment in both dietary groups, remained significantly elevated at 9 h after treatment, and had returned to uninjected control levels by 12 h (Fig. 5C ). The increase in transgene expression at 6 h in SrCl 2 -treated OST2 mice (6.6 Ϯ 0.9-fold higher than uninjected values) was considerably lower than that observed in mice on the LowCa or HighCa diets treated with 1,25-(OH) 2 D 3 (23.6 Ϯ 3.6-and 25.2 Ϯ 7.7-fold, respectively). As previously noted for animals fed the HighCa diet, osteocalcin mRNA levels in both transgenic and nontransgenic mice fed LowCa and SrCl 2 diets were not altered by 1,25-(OH) 2 D 3 treatment ( Cellular responses to 1,25-(OH) 2 D 3 treatment were examined histologically. In situ hybridization analyses indicated that in femoral sections from all OST2 mice, the spatial distribution of transgene expression was unchanged in hormone-treated animals, with strong staining in trabecular and endosteal osteoblasts, in osteocytes close to bone-forming surfaces and in hypertrophic chondrocytes (Fig. 6A ). With reduced CAT probe concentration, only the most strongly transgene-expressing cells were positively stained (Fig. 6B , 0-h sample).
At 6 h after 1,25-(OH) 2 D 3 injection, the number of cells positive for transgene mRNA expression using the low probe concentration was dramatically increased in all three dietary groups. Transgene expression was also increased at 3 and 9 h after treatment, but the maximal level of staining consistently occurred at 6 h. Intense staining was seen in the same cell types and along the same surfaces that stained positive using high CAT probe concentration in uninjected animals (compare Fig. 6A with 6B, 6-h sample). At 12 ( Fig. 6B ) and 24 (not shown) h after injection, the number of strongly positive cells had returned to levels observed in uninjected controls (Fig. 6A ) or in vehicletreated animals (Fig. 6C) . In OST1 mice (even using the high probe concentration) transgene expression, which was below the level of detection in uninjected and vehicle-treated mice, was apparent at 6 h after 1,25-(OH) 2 D 3 treatment in osteoblasts in the primary spongiosa and in some hypertrophic chondrocytes and was again undetectable at 24 h after treatment (not shown).
The distribution of transgene expression mirrored osteocalcin expression detected by in situ hybridization at the high probe concentration (Fig. 6D ). Consistent with the Northern blot results, expression of the endogenous mouse osteocalcin mRNA was not in- 
DISCUSSION
The osteoblast-targeting vector, OSCAT8, with 5Ј-and 3Ј-flanking sequences from the human osteocalcin gene, directed reporter gene expression specifically to osteoblastic lineages in transgenic mice. The levels of transgene mRNA and transgene activity were high in bone, and levels in nonosseous tissues were comparable to nontransgenic levels. Brain and kidney tissue extracts yielded no detectable CAT activity or RNA in the OSCAT8 mice. The histological pattern of transgene expression closely followed osteocalcin expression and was comparable to in situ hybridization patterns of osteocalcin expression in rat femurs (5, 6, 41) . Transgene and osteocalcin expression were detected in osteoblasts, osteocytes, and hypertrophic chondrocytes in the present study. Although some osteocalcin expression was detectable in megakaryocytes (7), transgene expression was not detected in bone marrow megakaryocytes in this study, even after 1,25-(OH) 2 D 3 treatment. It is not clear whether the previously reported low levels of osteocalcin gene expression in megakaryocytes (7) and brain, intestine, and kidney (8) are derived from the osteocalcin genes or from the osteocalcin-related genes described in mice and rats. If osteocalcin expression does occur in human megakaryocytes, data from the present study indicate either that such expression is directed by regions of the osteocalcin promoter not included in the 5Ј-and 3Ј-sequences in the OSCAT8 construct or that the human sequences present in the transgene do not function in murine megakaryocytes.
The pattern of transgene expression seen in the OST sublines is similar to those reported in previous studies utilizing varying extents of 5Ј-flanking sequences from the human and rat osteocalcin genes, with the exception that all previous reports have demonstrated ectopic transgene expression in kidney and/or brain (42) (43) (44) . Although the present study suggests a regulatory role for the 3Ј-flanking sequence, this possibility cannot be confirmed because there has been no direct comparison of constructs with and without this 3Ј-sequence.
In situ hybridization analysis demonstrated that after 1,25-(OH) 2 D 3 treatment, the spatial pattern of the increased transgene expression was unchanged. Before hormone treatment, although there was extensive transgene expression in trabecular and endosteal osteoblasts as well as in osteocytes and hypertrophic chondrocytes, only a few cells of each type exhibited a high level of transgene expression. After 1,25-(OH) 2 D 3 treatment, the number of trabecular and cortical osteocytes and hypertrophic chondrocytes ex- pressing high levels of the transgene was increased, supporting a function for vitamin D receptors in hypertrophic chondrocytes (45, 46) and suggesting a presence of functional receptors in osteocytes. 1,25-(OH) 2 D 3 regulation of collagen gene products has been described in hypertrophic chondrocytes (40, 47) , but regulation of a noncollagenous protein in this cell type has not previously been described.
Whereas the basal transgene expression pattern closely followed endogenous osteocalcin gene expression in bone cells, the hormone responsiveness of the human-derived transgene differed from that of the endogenous gene. In both primary cell culture and whole animal studies, expression of the human osteocalcin-directed transgene was markedly increased by 1,25-(OH) 2 D 3 treatment. In the same experiments and in nontransgenic controls, however, hormone treatment did not significantly alter levels of mouse osteocalcin protein in vitro, osteocalcin mRNA levels in vivo, or serum osteocalcin levels over the time course studied, indicating a species-related difference in osteocalcin promoter responses to 1,25-(OH) 2 D 3 treatment.
Other studies have also indicated a minimal response of the mouse osteocalcin gene to 1,25- (38) ; rather, indirect regulation via decreased activity of the OSF2 transcription factor was proposed (34) . In another study, 1,25-(OH) 2 D 3 caused a decrease in osteocalcin release into culture supernatant of the murine osteoblast-like cell line MC3T3-E1, whereas in the same cell line, a stably transfected rat osteocalcin promoter construct responded positively to 1,25-(OH) 2 D 3 treatment. Moreover, in transient transfections, activity of a reporter construct bearing the mouse osteocalcin VDRE fused to a minimal TATA-containing promoter was repressed by 1,25-(OH) 2 D 3 treatment, whereas the activity of an analogous construct bearing the rat VDRE sequence was stimulated by the hormone treatment (39) . Contrary to the previous report, however, this latter study also demonstrated that the mouse osteocalcin VDRE is bound by a complex containing VDR and RXR␣ in gel mobility shift assays, a difference from the previously cited work that may stem from variation in probe length in the two studies. Despite this difference, the common finding in those published studies, that 1,25-(OH) 2 D 3 reduces mouse osteocalcin expression to a significant extent, differs from those of the present study. Whether these differences relate to duration of hormone treatment, extent of mineraliza- Although osteocalcin and VDR do not appear to be required for embryonic development in the mouse (11, 51) , they clearly play important roles in postnatal bone physiology. In mice lacking functional osteocalcin genes, bone density is increased with apparently elevated osteoblast activity, suggesting a role for osteocalcin in limiting bone formation in the mouse (11) . Similarly, growth retardation and widening of the growth plate are observed in VDR knockout mice, although serum osteocalcin levels are not altered (51) . These alterations in bone structure are similar to those seen in vitamin D-deficient states in human (52, 53) and rat (54) (55) (56) . Thus, although the interaction between 1,25-(OH) 2 D 3 and bone is important for postnatal bone growth, the present study suggests VDREmediated up-regulation of osteocalcin is not required for this process in the mouse. By extension, 1,25-(OH) 2 D 3 regulation of osteocalcin expression may not be involved in bone growth in humans. Alternatively, the physiological role of VDRE-mediated osteocalcin regulation may differ between species.
Given the murine-human difference in osteocalcin regulation by 1,25-(OH) 2 D 3 described here, it is important that an appropriate model be used to study the physiological regulation of the human osteocalcin gene. The OSCAT8 transgenic mouse may represent such a model, utilizing 5Ј-and 3Ј-human osteocalcinflanking regions to direct transgene expression and mimic the human osteocalcin gene in both expression pattern and 1,25-(OH) 2 D 3 regulation. In conjunction with other reports, the present study provides strong evidence for a species-related difference in the effect of 1,25-(OH) 2 D 3 on VDRE-mediated regulation of osteocalcin transcription in the mouse and human, with a 1,25-(OH) 2 D 3 -stimulated increase in the human osteocalcin-directed transgene without a concomitant increase in endogenous mouse osteocalcin transcription. This species difference in 1,25-(OH) 2 D 3 responsiveness relates to sequence variations in osteocalcin gene-regulatory regions rather than inherent differences in the bone cellular milieu. Insights gained from further investigation of these species-related differences may shed light on the function of osteocalcin and its regulation by vitamin D in bone physiology.
MATERIALS AND METHODS
DNA Constructs and Probes
The pOSCAT8 construct contained the CAT reporter gene flanked by 5Ј-and 3Ј-regions of the human osteocalcin gene in natural position and orientation. The 3.8 kb of continuous 5Ј-flanking sequence, including a known VDRE (25, 26) , was generated by inserting a 3.5-kb HindIII-SacI fragment of genomic DNA (26) into the SacI site at position Ϫ344 of the human osteocalcin gene in the pOSCAT1 construct (26) . A 3.5-kb BamHI-HindIII fragment from the human osteocalcin gene including 108 bp of exon 4 and 3.4 kb of 3Ј-untranslated and flanking DNA was inserted downstream of the SV40 polyadenylation signal.
Southern blots were probed with a CAT-specific DNA probe (1.8 kb BglII-BamHI fragment from the pCAT-promoter vector (Promega, Madison, WI) or with a probe specific for the human osteocalcin 3Ј-sequence (1.1 kb KpnI fragment from pOSCAT8 containing human osteocalcin 3Ј-flanking DNA). DNA slot blots were probed for the mouse neurofilament gene (57) and subsequently with the human osteocalcin 3Ј-probe. Northern blots were probed with random primed CAT-specific DNA probe or osteocalcin-specific probe and subsequently with a 32 P-kinased oligonucleotide probe for 18S ribosomal RNA (5Ј-CGGCATGTATTAGCTCTAGA-ATTACCACAG-3Ј).
For in situ hybridization, riboprobes were generated from linearized pOC918 construct containing a rat osteocalcin cDNA insert (a gift from Dr. S. E. Harris). For the CAT probes, a 1.7-kb HindIII fragment of the pCAT-promoter vector was subcloned into pGEM-II to form pGEMCAT6, which was linearized and transcribed to generate the antisense strand CAT riboprobe. A reverse orientation construct (pGEMCAT2) was similarly transcribed to generate the sense strand riboprobe.
Generation of Transgenic Mice and Genomic DNA Analysis
Transgenic mice were generated by pronuclear injection of the purified HindIII insert from pOSCAT8 into inbred FVB/N embryos (58) and screened by Southern blot analysis of genomic DNA prepared from tail biopsy. Upon back-crossing the founder animal to FVB/N, two transgene insertions segregated. Inbred sublines (OST1 and OST2) with stable transgene transmission patterns were generated by back-crossing to FVB/N mice for two further generations before interbreeding hemizygous siblings. Eight-week-old hemizygous transgenic animals were bred from homozygous sires and nontransgenic FVB/N dams for all studies. Nontransgenic FVB/N mice were specifically bred as age-matched controls for these experiments. All experimental animals and mice used to generate transgenic lines were bred at the Garvan Institute in studies approved by the Institute Animal Experimentation Ethics Committee.
Quantitative slot blot analysis was performed using 5 g DNA and probed with the mouse neurofilament probe and quantitated on a Molecular Dynamics 445 SI PhosphorImager (Sunnyvale, CA). The filter was stripped then reprobed with the transgene-specific 3Ј-osteocalcin DNA probe and quantitated. Transgene copy number was calculated by normalization to the neurofilament signal. In these two sublines of OSCAT8 transgenic mice, quantification of the number of incorporated copies of the transgene showed low and high copy number insertions, with OST1 and OST2 containing 2 and 60 transgene copies per haploid genome, respectively.
Primary Bone Cell Isolation and Culture
Osteoblast-like cells were derived from 3-to 6-day-old FVB/N and OST2 mice as follows (59) . Frontal and parietal bones were removed and washed twice in PBS, and adherent soft tissue and sutures were dissected away. Cleaned calvariae were transferred to culture medium containing 30 mM HEPES. Bones were washed again and minced into normal culture media (␣-MEM) containing 10% FCS, 100 U/ml penicillin, 100 g/ml streptomycin, 40 g/ml gentomycin, 10 mM ␤-glycerophosphate, 50 g/ml ascorbic acid, 20 mM HEPES, 2 mM glutamine. Calvariae were washed in PBS and transferred to 1 ml digest mix per five calvaria [1 mg/ml collagenase (Boehringer-Mannheim, Mannheim, Germany), 0.05% trypsin, 0.02% EDTA in PBS] and stirred vigorously for 30 min at 37 C. Five sequential digests were carried out; the last three were washed in PBS and resuspended in fresh culture medium, pooled, aspirated repeatedly through 19-and 21-gauge needles, and filtered through a 200-m polyester filter (Spectrum Industries, Houston, TX) to a single cell suspension. Cells were seeded at a density of 10 4 cells per cm 2 into six-well plates and cultured in a humid atmosphere with 5% CO 2 at 37 C. Medium was changed after 3 days and every 2-3 days thereafter. Mineralizing cultures were treated with 10 Ϫ8 M 1,25-(OH) 2 D 3 from day 29 and stopped on day 35; untreated controls were stopped on day 35.
DNA, CAT, and Protein Assays
Cells were lysed in 500 l 0.1% Triton-X100, 0.5 mM MgCl 2 in 20 mM Tris, pH 10, and stored at Ϫ20 C until assayed. The fluorometric DNA assay was adapted from Rao and Otto (60) and Downs and Wilfinger (61) . Duplicate samples of 50 l lysate were mixed with 200 ml of 1 g/ml bisbenzimide in water in clear polystyrene 96-well plates, allowed to stand for 5 min, then read on a Fluoroskan II (Labsystems, Helsinki, Finland) with excitation and emission settings at 355 nm and 460 nm, respectively. DNA values were calculated using DeltaSoft analytical software (Biometallics, Princeton, NJ).
For the CAT and protein assays the same cell lysates were freeze-thawed three times to further release cellular proteins. A 1-h 65 C incubation to inactivate nonspecific acetyl transferases was carried out. CAT was assayed as described by Morrison et al. (26) based on the nonchromatographic assay of Sleigh (62) . Protein was assayed using the Bio-Rad (Hercules, CA) protein assay based on the colorimetric method of Bradford (63) .
Osteocalcin levels in the culture medium were determined by RIA using the method of Gundberg et al. (64) except sample sizes assayed were 50 l instead of 5 l. The concentration of primary antibody was altered accordingly to maintain the same total assay volume. Primary antibody and osteocalcin standards were kindly provided by Dr. C. Gundberg. Iodinated osteocalcin was purchased from Biomedical Technologies, Inc (Stoughton, MA). Donkey anti-goat IgG secondary antibody was purchased from Sigma (St. Louis, MO).
1,25(OH) 2 D 3 Treatment in Vivo
Animals were maintained on standard laboratory chow (Barastoc, Ridley Agri Products, Victoria, Australia) containing 0.94% calcium, 0.81% phosphorus, and 1800 IU vitamin D 3 /kg and supplied with water ad libitum. Ten days before treatment, at 6.5 weeks of age, animals were allocated one of three diets: standard laboratory chow (HighCa); semisynthetic AIN-93 diet (65) containing 0.1% calcium, 0.27% phosphorus, and 1800 IU vitamin D 3 /kg (LowCa); or vitamin D metabolism-inhibiting diet containing 0.1% calcium, 0.27% phosphorus, no vitamin D 3 , and 0.8% strontium chloride (SrCl 2 ) added to AIN-93. At 8 weeks of age, animals were given a single intraperitoneal injection of 1,25-(OH) 2 D 3 in 10% argon-saturated isopropanol/90% propylene glycol at a dose rate of 2 g/kg body weight or an equivalent volume of vehicle (0.1 ml). At various times after injection, animals were bled by cardiac puncture under methoxyflurane anesthesia (Metofane, Pittman-Moore, Mundelein, IL) and killed by cervical dislocation. Femurs, tibias, calvariae, brain, kidney, muscle, heart, lung, spleen, and liver were collected at the time of death and from uninjected mice at the time of injection. One femur, taken for in situ hybridization, was immediately fixed in 4% paraformaldehyde/PBS at 4 C overnight.
Other tissues collected were snap-frozen in liquid nitrogen and stored at Ϫ70 C until RNA preparation. Serum was prepared from blood and stored at Ϫ70 C before serum osteocalcin measurement (64) .
Initial experiments, repeated three times, included OST1, OST2, and FVB/N animals fed only the HighCa diet. Tissues were collected at the time of injection or at 6 or 24 h after injection. In subsequent comparisons of OST2 and FVB/N mice fed the LowCa and SrCl2 diets, tissues were collected at the time of injection or at 3, 6, 9, 12, or 24 h after injection. These experiments were repeated five times. For all experiments, at each repetition, single animals were injected with hormone or vehicle for each time point. Each experiment was analyzed once by Northern blot.
Preparation and Analysis of RNA
Tissues were homogenized at 3000-5000 rpm for 15 sec in 4.5 ml guanidine thiocyanate buffer (4 M guanidinium isothiocyanate, 0.5% sarkosyl, and 0.1 M ␤-mercaptoethanol) using a Polytron (Brinkman, Westbury, NJ). Total cellular RNA was isolated from homogenates by acid phenol-chloroform extraction (66) followed by cesium chloride gradient centrifugation (67) . RNA (15 g) was analyzed by Northern blot analysis on a nylon filter (HybondNϩ, Amersham, Buckinghamshire, UK) and probed with the random primed ␣-32 P-CTP-labeled CAT probe followed, after stripping, by the human osteocalcin probe, then the ␥-[ 
Histology
Skull, vertebrae, tibia, and femur samples were fixed in 4% paraformaldehyde/PBS at 4 C. Skulls were bisected sagittally during fixation. Femurs were trimmed and the distal third of each was used for analysis. Specimens were decalcified for 4 days in 15% EDTA/0.5% paraformaldehyde/PBS at 4 C and embedded in paraffin. Sections (5 m) were taken onto chrome alum-coated slides, dewaxed in Histoclear (National Diagnostics, Atlanta, GA), and rehydrated in graded ethanols followed by PBS before staining.
For immunohistochemistry, sections were blocked using 5% normal goat serum and incubated for 1 h at room temperature with a rabbit polyclonal anti-CAT antibody (5 Prime 3 3 Prime Inc., Paoli, PA) diluted 1:100 in PBS containing 2% normal goat serum. Endogenous peroxidase was blocked with 0.3% hydrogen peroxide, followed by a 30-min incubation with 0.3% biotinylated goat anti-rabbit IgG and an avidin-biotinylated peroxidase complex (Vector Laboratories, Burlingame, CA). Peroxidase was detected with a diaminobenzidine staining kit (Vector Laboratories). For quantification of immunohistochemical CAT staining, six femoral sections at 10-m intervals were analyzed from each of five 8-week-old transgenic mice. CAT surface as a percentage of total trabecular bone surface was determined in the metaphysis of each section using the Osteomeasure system (Osteometrics Inc., Decatur, GA).
In situ hybridization was modified from Zhou and colleagues (68) . Rat osteocalcin and CAT antisense and sense probes were generated as described above. Sections were incubated with 0.2 M HCl for 20 min at room temperature, followed by digestion with 1 g/ml proteinase K in 0.1 M Tris buffer (pH 8.0) for 45 min at 37 C, followed by 2 mg/ml glycine in PBS for 5 min. The tissues were refixed in 4% paraformol saline for 15 min before acetylation in 0.25% acetic anhydride/0.1 M triethanolamine (pH 8.0) for 10 min and rinsed in PBS between all pretreatments. Slides were stained for 1 h at room temperature with Fast Red TR (Sigma) to eliminate endogenous alkaline phosphatase staining and washed for 20 min in absolute ethanol before rehydration in PBS. Prehybridization was performed at room temperature for 30 min, followed by 2 h at 37 C in hybridization buffer: 50% formamide, 5ϫ NaCl-sodium citrate (SSC), 2% block reagent (Boehringer Mannheim) 0.1% N-lauroyl-sarcosine, and 0.02% SDS. Digoxigenin-labeled probes were applied in hybridization buffer at concentrations described below before incubation for 16-18 h at 42 C in a humidified chamber. Slides were washed in 2ϫ SSC, then 1ϫ SSC, and finally 0.1ϫ SSC, each for 30 min at 37 C. Hybridized probe was detected using the alkaline phosphatase-coupled antidigoxigenin antibody method (Boehringer Mannheim) with the addition of 1.2 mg/ml levamisole (Sigma) in the final staining solution.
Osteocalcin and CAT mRNA transcripts were initially detected using 7.5 ng and 15 ng probe/slide, respectively, for in situ hybridization. However, with these excess probe concentrations, the transgene signal was so strong that it was not possible to detect the increase in transgene RNA that had been documented using Northern blot analysis. Therefore, reduced probe concentrations were empirically chosen based on hybridization to control sections of uninjected OST2 femurs until a minimal level of osteocalcin and CAT mRNA staining was observed, thus allowing detection of even small changes in expression. Final concentrations used for 1,25-(OH) 2 D 3 treatment experiments were 0.75 ng/slide and 1.5 ng/slide for osteocalcin and CAT, respectively.
Femoral sections were also stained for tartrate-resistant acid phosphatase using a method modified from Parkinson et al. (69) by inclusion of tartaric acid in the staining and prestaining buffers with a hematoxylin counterstain. Some femoral sections stained for CAT by immunohistochemistry were also stained for tartrate-resistant acid phosphatase before immunohistochemical staining. Sections were photographed using a Zeiss Axiophot microscope (Carl Zeiss, Thornwood, NY) with differential interference contrast optics at all magnifications shown.
Statistical Analysis
Treatment responses of mRNA expression and serum osteocalcin were compared by one, two, and three-way ANOVA followed by Tukey's post-hoc test. In all analyses, P Ͻ 0.05 was considered significant. Histomorphometric measurements are expressed as the mean Ϯ SEM from five femoral sections from each of six animals.
